Media stories about Amedisys (NASDAQ:AMED) have trended positive on Saturday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amedisys earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave media headlines about the health services provider an impact score of 100 out of 100, meaning that recent media coverage is extremely likely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- Amedisys Inc (AMED) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Amedisys : Wins Five National Marketing Awards (4-traders.com)
- Amedisys Wins Five National Marketing Awards (finance.yahoo.com)
- Home health firm to pay investors $43.8M in lawsuit (neworleanscitybusiness.com)
- Can analysts adopt a bullish outlook for Amedisys Inc (NASDAQ:AMED)? (campdesrecrues.com)
A number of brokerages have recently issued reports on AMED. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research report on Monday, April 17th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 price target on shares of Amedisys in a research report on Monday, June 5th. Stephens upped their price target on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 4th. Benchmark Co. reaffirmed a “hold” rating and set a $57.00 price target (up from $50.00) on shares of Amedisys in a research report on Wednesday, May 3rd. Finally, Mizuho raised Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price target on the stock in a research report on Wednesday, May 3rd. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $58.38.
Amedisys (NASDAQ:AMED) opened at 65.46 on Friday. Amedisys has a 52-week low of $34.58 and a 52-week high of $65.91. The company has a 50 day moving average price of $60.21 and a 200 day moving average price of $50.83. The firm has a market capitalization of $2.21 billion, a P/E ratio of 48.49 and a beta of 0.99.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, May 2nd. The health services provider reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.06. Amedisys had a net margin of 3.16% and a return on equity of 12.60%. The business had revenue of $370.46 million for the quarter, compared to analyst estimates of $370.03 million. During the same period in the previous year, the business posted $0.33 earnings per share. On average, equities analysts forecast that Amedisys will post $2.07 EPS for the current fiscal year.
In related news, insider Scott G. Ginn sold 23,828 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $58.62, for a total transaction of $1,396,797.36. Following the transaction, the insider now owns 13,018 shares of the company’s stock, valued at $763,115.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jake L. Netterville sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the transaction, the director now directly owns 77,499 shares in the company, valued at approximately $4,649,940. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,828 shares of company stock worth $3,350,922. 2.80% of the stock is owned by insiders.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/amedisys-amed-earns-media-sentiment-score-of-0-26/1936455.html
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.